Clinical · Molecular biology
Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
This study analyzed a cohort of 1,254 patients with biliary tract cancer to assess the utility of targeted NGS molecular profiling. It revealed that 59% of patients harbored at least one OncoKB alteration, and 32.2% had level 1/2 alterations, with varying frequencies across tumor locations. Targeted therapies were associated with improved progression-free survival but not overall survival. The study also identified co-occurring alterations and acquired resistance mechanisms, such as ERBB2 loss or alterations in the RAS, MEK, MET, MYC, and CDKN2A pathways. These findings highlight genomic heterogeneity and the importance of precision medicine in informing future drug development efforts.